CSPC and AstraZeneca Joint Venture: A New Logic for MNCs to “Build Factories” in China
A British pharmaceutical giant has decided to build its most advanced production line in Shijiazhuang, a second-tier city on the North China Plain. On August 5, AstraZeneca and CSPC Pharmaceutical Group (or CSPC) signed an agreement to establish a joint…
Xgene secured RMB 250 million in series D financing to develop novel non-opioid analgesic drugs
Recently, Xgene Pharmaceutical Inc. (“Xgene”), a company focusing on the research and development of innovative drugs in the fields of pain and neurology, completed a RMB 250 million Series D financing round. This round was jointly led by Yifeng…
Aiming at an ‘Undruggable” target, Pyrotech’s class 1 small-molecule candidate gets approved for sepsis clinical trials
On August 4, Pyrotech Therapeutics (“Pyrotech”) announced that its independently developed small-molecule pyroptosis inhibitor, PTT-121, has been approved for clinical trials in China, intended for the treatment of sepsis and septic shock.…
Alphamab Oncology and Pathos reach international licensing agreement for TROP2/HER3 bispecific ADC.
On August 4, Alphamab Oncology (“Alphamab”) announced a licensing agreement with Pathos AI (“Pathos”) for its proprietary, “First-in-Class” TROP2/HER3 bispecific antibody-drug conjugate (ADC), JSKN016. Under the…
Kelun Biotech seeks marketing approval on sac-TMT for the first-line treatment of PD-L1-negative TNBC
On July 30, 2026, Sichuan Kelun Biotech Co., Ltd. (“Kelun”) announced that its independently developed antibody-drug conjugate (ADC) targeting human trophoblast surface antigen 2 (TROP2), sac-TMT (also known as SKB264/MK-2870) (Gitalay®), has…
XellSmart’s universal cell therapy drug for Parkinson’s disease receives Fast Track designation from the US FDA
On July 28, 2026, XellSmart Bio‘s independently developed allogeneic universal “off-the-shelf” XS411 cell therapy injection, for the treatment of Parkinson’s disease, the world’s second most prevalent neurodegenerative…
Hansoh’s HS-20093 met its Phase 3 goals, strengthening its status as a top B7-H3 ADC contender.
In less than a month, Hansoh Pharmaceutical‘s B7-H3 targeted antibody-drug conjugate (ADC) HS-20093 (Risvutatug Rezetecan) achieved two globally significant clinical breakthroughs. On July 28, Hansoh announced that the ARTEMIS-011 Phase III…
Haisco’s class 1 small-molecule PNH drug has been approved for marketing in China
Today (July 23), the National Medical Products Administration (NMPA) of China announced that it has approved the marketing of Haisco Pharmaceutical‘s Class 1 innovative drug, Succinate Spocoman tablets (HSK39297), through the priority review and…